Tigatuzumab

From Self-sufficiency
Jump to: navigation, search
Tigatuzumab
Monoclonal antibody
Type Whole antibody
Source Template:Infobox drug/mab source
Target TNFRSF10B (TRAIL-R2)
Identifiers
CAS Number 918127-53-4
ATC code none
Chemical data
Formula C6406H9924N1716O2012S46
Molar mass 144.6 kDa[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Tigatuzumab (CS-1008) is a monoclonal antibody[1] for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer has been completed,[2] Phase II trials for colorectal cancer[3] and non-small cell lung cancer[4] are running, and a study for ovarian cancer has been approved.[5]

The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.[6]

References

  1. WHO Drug Information
  2. NCI: Combination Therapy Targets Pancreatic Cancer Stem Cells
  3. NCI: CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
  4. NCI: CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
  5. NCI: Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
  6. NCI: CS-1008